← FDA Drug Approvals (Drugs@FDA)

OMLONTI

NDA · New Drug Application · Sponsor: OCUVEX THERAP · Approved 2022-09-22

Drug application

FDA Application #

NDA215092

Application type

New Drug Application

Brand name

OMLONTI

Generic name

OMIDENEPAG ISOPROPYL

Active ingredients

OMIDENEPAG ISOPROPYL

Dosage form

SOLUTION

Route

OPHTHALMIC

Marketing status

Prescription

Sponsor

OCUVEX THERAP

Manufacturer

Ocuvex Therapeutics, Inc.

First approval

2022-09-22

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown